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Abstract: Secretome and extracellular vesicles (EVs) are considered a promising option to exploit
mesenchymal stem cells’ (MSCs) properties to address knee osteoarthritis (OA). The aim of this
systematic review was to analyze both the in vitro and in vivo literature, in order to understand the
potential of secretome and EVs as a minimally invasive injective biological approach. A systematic
review of the literature was performed on PubMed, Embase, and Web of Science databases up
to 31 August 2019. Twenty studies were analyzed; nine in vitro, nine in vitro and in vivo, and two
in vivo. The analysis showed an increasing interest in this emerging field, with overall positive
findings. Promising in vitro results were documented in terms of enhanced cell proliferation, reduction
of inflammation, and down-regulation of catabolic pathways while promoting anabolic processes.
The positive in vitro findings were confirmed in vivo, with studies showing positive effects on cartilage,
subchondral bone, and synovial tissues in both OA and osteochondral models. However, several
aspects remain to be clarified, such as the different effects induced by EVs and secretome, which is the
most suitable cell source and production protocol, and the identification of patients who may benefit
more from this new biological approach for knee OA treatment.
Keywords: Exosome; extracellular vesicles; mesenchymal stem cell; knee osteoarthritis; injection
1. Introduction
Osteoarthritis (OA) is a degenerative disease with progressive degradation of articular cartilage
and subchondral bone leading to loss of joint function and pain which significantly impairs patient
quality of life [1,2]. Worldwide estimates indicate that 9.6% of men and 18.0% of women over 60 years
old suffer from symptoms of OA, with knee OA representing one of the most disabling conditions,
with a huge social impact [3–5]. This high prevalence of OA is further increasing due to the augmented
risk of OA due both to non-modifiable risk factors, such as the aging population and the gender,
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and to local risk factors, such as physical activity [6]. The classic clinical approaches in the treatment
of OA offer mainly temporary symptom relief without disease modifying effects [7]. The limitations
of available treatments fostered the development of new strategies, with cell-based procedures being
proposed, such as minimally invasive injective approaches with the aim of modulating the inflammation
process as well as stimulating and supporting the regeneration of articular tissues, thus re-establishing
joint homeostasis. Mesenchymal stem cells (MSCs) represent the most promising cell population [8,9]
showing, in several clinical studies, the possibility to increase joint function and reduce pain in knee
OA patients [10–12]. However, the efficacy of this cell injection approach may be impaired by cell
manipulation, and its wide application is strongly limited by regulatory issues [13,14].
To overcome these limitations, in the past 15 years researchers focused on the secretome of MSCs.
In fact, it has been demonstrated that the therapeutic ability of MSCs is mainly related to their secretion
of biologically active factors, rather than their differentiation properties [15]. These soluble factors
belong to different biochemical classes and include growth factors, cytokines, chemokines, lipids,
and other molecules with immunomodulatory effects [15]. All these paracrine factors, with the addition
of a broad variety of acid nucleic and different lipids, can also be found within cell-secreted vesicles
(extracellular vesicles (EVs)), a key part of the secretome which is gaining increasing attention by
the scientific community. EVs (either microvesicles (MVs) or Exosomes (Exo)) represent important
mediators between articular cell types [16]. Once secreted in the extracellular space, they can interact
and be internalized by target cells, ultimately influencing and modifying their phenotype. Preclinical
in vitro studies suggested a wide range of potential benefits with immunomodulatory, regenerative,
anti-catabolic, and chondro-protective properties of secretome and EVs, which could overcome the
limits of cell therapies while offering comparable biological effects. However, while secretome and EVs
appear to be very promising, it is important to confirm their role and effects in the complex in vivo
environment of knee OA joints [17].
Therefore, the aim of this systematic review was to analyze the available literature on both in vitro
and in vivo settings, in order to understand the potential of secretome and EVs as a minimally invasive
injective biological approach for the treatment of knee OA.
2. Materials and Methods
2.1. Data Source
A systematic review of the literature was performed on the use of secretome and EVs in both
in vitro and in vivo studies for the treatment of OA affecting the knee joint. This search was performed
on PubMed, Embase, and Web of Science databases up to the 31 August 2019 using the following
string: (exosom* OR microvesicle* OR vesicle* OR ectosom* OR secretome) AND (mesenchymal stem
cell* OR MSC* OR mesenchymal stromal cell* OR ASC* OR ADSC* OR BMC OR BMSC* OR stem cell*)
AND (cartilage OR synovi* OR menisc* OR chondrocyte OR chondral OR osteoarthritis OR OA).
2.2. Study Selection Process
Two independent reviewers (A.R. and D.D.) conducted the screening process and the analysis
of the papers according to PRISMA guidelines. First, the reviewers screened the resulting records by
title and abstract, then the full text of selected manuscripts was screened entirely according to the
following inclusion criteria: in vitro and in vivo studies of any level of evidence, written in English
language, on the use of secretome and EVs for the treatment of cartilage lesions and OA with focus on
the knee joint. Exclusion criteria were articles written in other languages, reviews, studies not analyzing
the effect of secretome and EVs or exploiting their potential effect not in the knee. The reviewers also
screened the reference lists of the selected papers. The flowchart reported in Figure 1 graphically
describes the systematic review process.
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Figure 1. PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analysis) flowchart 
of the systematic literature review. 
2.3. Data Extraction and Synthesis 
From the included studies, relevant data were extracted, summarized, and analyzed according 
to the purpose of the present work. In particular, the following data were evaluated: cell source of 
secretome and EVs, target cell types, type of the secreted products (divided in secretome, Exo, and 
MVs, Figure 2), production method, storage, and study design; for the in vivo studies, the animal 
model was also considered together with the method of OA induction; in vitro effects were evaluated 
in terms of EVs internalization, effect on viability, proliferation and migration, effect on chondrocyte 
phenotype, production of cartilaginous ECM, anti-catabolic effect, anti-inflammatory and 
immunomodulatory effect, effect on apoptosis, autophagy, and senescence; the in vivo effects were 
evaluated in terms of effect on cartilage tissue and ECM deposition, effect on synovial inflammation 
and cytokines, effect on bone tissue, effect on pain, and gait. 
Figure 1. PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analysis) flowchart
of the systematic literature review.
2.3. Data Extraction and Synthesis
From the included studies, relevant data were extracted, summarized, and analyzed according
to the purpose of the present work. In particular, the following data were evaluated: cell source
of secretome and EVs, target cell types, type of the secreted products (divided in secretome,
Exo, and MVs, Figure 2), production method, storage, and study design; for the in vivo studies,
the animal model was also considered together with the method of OA induction; in vitro effects were
evaluated in terms of EVs internalization, effect on viability, proliferation and migration, effect on
chondrocyte phenotype, production of cartilaginous ECM, anti-catabolic effect, anti-inflammatory and
immunomodulatory effect, effect on apoptosis, autophagy, and senescence; the in vivo effects were
evaluated in terms of effect on cartilage tissue and ECM deposition, effect on synovial inflammation
and cytokines, effect on bone tissue, effect on pain, and gait.
J. Clin. Med. 2019, 8, 1867 4 of 16
J. Clin. Med. 2019, 8, x FOR PEER REVIEW 4 of 16 
 
 
Figure 2. Schematic representation of secretome components. 
3. Results 
According to the search strategy, 154 papers were found from PubMed, 148 from Embase, 206 
from Web of science. After duplicates removal, 20 papers were analyzed, nine of those were in vitro 
studies, nine were in vitro and in vivo, and two were in vivo studies. The in vitro studies have been 
described in detail in Table 1 while Table 2 pools together studies performed both in vitro and in vivo 
and those in vivo only. All these studies have been summarized in the following paragraphs.
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Table 1. Details of papers with in vitro experiments. Abbreviations: hBMSCs, human bone marrow-derived mesenchymal stem cells; Exo, exosome; EV, extracellular
vesicles; HA, hyaluronic acid; ASC, adipose-derived mesenchymal stem cells; MVs, microvesicles; CM, conditioned medium; FLS, fibroblast-like synoviocytes.
References Cell types Secretome/Vesicle Types Isolation Method and Storage Study Design Results
Niada et al. 2019
Stem Cell Res
Source: Human ASCs
(2 males + 6 females;
mean age: 46 ± 16 years)
Target: Human chondrocytes
(11 males + 7 females;
mean age: 62 ± 11 years)
Secretome
Cell Passage: NA
Secretome collected after 72 h
of ASCs starvation (ca 106 ASCs)
CH + TNFa vs. CH +
TNFa + ASCs-secretome
No alteration on chondrocytes viability.
Secretome addiction reduce osteocalcin, collagen X
(anti-hypertrophic effect)
MMP3, 13 activity reduction correlated to the
abundance of TIMPs in secretome (anticatabolic effect)
Sun et al. 2019
J Cell Biochem
Source: Human BMSCs
(3 males; mean age: 27, 3 years)
Target: Human chondrocytes





Storage at −80 ◦C
hBMSC-320c-Exos vs.
hBMSC-Exo vs. PBS
Increase of chondrocyte proliferation
in hBMSC-320c-Exo group than other Exo,
with down-regulated MMP 13 and up-regulated
Sox 9 expression during hBMSC
chondrogenic differentiation.
Ragni et al. 2019
Stem Cell Res & Ther
Source: Human ASCs
(3 females; mean age: 54 ± 8 years)
Target: Human fibroblast-like synoviocytes
(3 females; mean age: 72 ± 7 years)
EVs
(40–400 nm)
Cell passage: range 3–5
Isolation method:
Differential centrifugation
Storage: at 4 ◦C if used within 2 days
or −80 ◦C
EVs vs. EVs + HA
HA is involved in EV internalization
EVs reduced the expression of pro-inflammatory
cytokines and chemokines
in a chronic model of FLS inflammation
Qi et al. 2019
In vitro cell & develop biology
Source: Rabbit BMSCs
(males; age: 4 weeks)
Target: Rabbit chondrocytes







BMSCs Exo vs. control
All changes induced by Il1b, as decreased cell
viability, increased apoptosis was abolished
by the addition of BMSCs-Exo.











MSC-Exo increased chondrogenic genes Col2a1
and aggrecan, decreased MMP-13 and Runx2.
Moreover, MSC-Exo induced cells proliferation
and cells apoptosis inhibition
Mao et al. 2018
J Cell Mol Med
Source: Human miR-95-5p- chondrocytes
(3 males + 3 females; mean age: 35 years)
Target: Human chondrocytes








AC Exo (10 µg vs. 50 µg)
50 µg Exo/mL AC-miR-95-5p-Exo showed greater
proliferation than those incubated with other doses.
Up-regulated the expression levels of aggrecan,
COL2A1, COL9A1, COMP. Decrease COL10A1,
MMP13, HDAC2-8
Vonk et al. 2018
Theranostic
Source: Human BMSCs
(1 male + 1 female; mean age: NA)
Target: Human chondrocytes
(5 female + 3 male; mean age: NA)
EVs
(40–150 nm)
Cell passage: BMSCs 4–7,
Chondrocytes 2
Isolation method:
Ultracentrifugation + sucrose density
Storage NA
EVs vs. CM vs. CM-EVs
BMMSC-EVs down-regulated COX-2,
pro-inflammatory interleukins and inhibited
TNF-alpha-induced collagenase activity.
Increase proteoglycans production
and type II collagen
Tofiño-Vian et al. 2018
Cell Physiol Biochem
Source: Human ASCs
(4 males + 7 females; mean age 53, 8 years)
Target: Human chondrocytes
(27 females + 14 males;
mean age: 65, 6 years)
MVs (mean 279 nm) and





MVs vs. Exo vs.
CM vs. control
MVs and Exo reduced the production of inflammatory
mediators (TNFα, IL-6, PGE2, NO)
Anti-inflammatory and chondroprotective effect
mediated by up-regulation of annexin1,
especially in MVs group
Tofiño-Vian et al. 2017
Oxid Med Cell Longev
Source: Human ASCs
(2 males + 2 females, mean age 54, 4 years)
Target: Human osteoblasts
(21 females + 9 males;
mean age: 68, 4 years)
MVs (mean 316 nm) and





MVs vs. Exo vs.
CM vs. control
CM, MVs, and Exo down-regulate senescence
activity and reduced the production
of inflammatory mediators
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Table 2. Details of studies with in vitro and in vivo experiments. Abbreviations: IPFP, infrapatellar fat pad MSCs; I.A., intra-articular; Exo, Exosome; BMSCs, bone
marrow-derived MSCs; MVs, microvesicles/microparticles; SMSC, synovial MSCs; ACs, articular chondrocytes; ES, embryonic stem cells; CM, conditioned medium;
iMSC, induced pluripotent stem cell-derived MSCs; ECM, extracellular matrix.
References Animal and OA Model Sources Secretome/Vesicle Types Isolation Method and Storage Study Design Results
In vivo studies







mean age 55.3 ± 10 years)
Secretome Cell Passage: 3Storage: −80 ◦C
MSCs secretome vs.
MSCs vs. medium
Pain reduction at day seven and better
cartilage repair for MSCs secretome and
MSC-groups compared to the control.
No effects on synovial inflammation,
subchondral bone volume or presence
of different macrophage subtypes











FiltrationStorage at −20 ◦C
Exo (100 mg) vs. PBS
In Exo group, complete restoration
of hyaline-like cartilage and subchondral
bone with good surface regularity,
complete bonding to adjacent cartilage,
and ECM deposition
In vitro and in vivo studies
















In vivo study 1
sham vs. PBS vs. Exo-IPFP
In vivo study 2
PBS + antagomir-NC
vs. PBS-ExoIPFP + antagomir-NC vs.
Exo-IPFP+ antagomir-100-5p
In vitro:
Cell apoptosis inhibition, matrix synthesis
promotion, reduction of catabolic markers
expression, enhance autophagy level via
mTOR inhibition
In vivo:
Exo significantly prevent cartilage
destruction and partially
improve gait abnormality.
I.A. of antagomir demolishes the
remedial effect of MSCs Exo















Exo vs. Exo- KLF3-AS1
In vivo
Normal vs. OA vs. PBS vs. MSCs-Exo
vs. MSCsi-KLF3-AS1-Exo
In vitro:
Exo KLF3-AS1 suppressed IL-1β-induced
apoptosis of chondrocytes and promote
chondrocytes proliferation.In vivo:
Exo-KLF3-AS1 promoted cartilage repair
in an OA rat model.
Mao G et al. 2018





(3 males + 3 females;




(3 males + 3 females;
mean age: 60.24 years)
Normal human
chondrocytes
(3 males + 3 female;
mean age: 54.46 years)
Exo
(50–150 nm)






Exo (50, 100, and 200 µg) vs.
miR-92a-3p-Exo (50, 100, and 200 µg)
vs. PBS for proliferation
For other tests 200 µg
In vivo:
MSC-Exo (500 µg/mL) vs.
MSC-miR-92a-3p-Exo (500 µg/mL) vs.
OA and normal groups
In vitro:
miR-92a-3p- Exo promoted higher cell
proliferation, matrix genes expression
in MSCs and chondrocytes,
respectively at 200 ug concentration
In vivo:
MSC-miR-92a-3p-Exo inhibited cartilage
degradation in OA model
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Table 2. Cont.
References Animal and OA Model Sources Secretome/Vesicle Types Isolation Method and Storage Study Design Results

















MVs 5 µL vs. MVs 10 µL vs.
MVs 20 µL vs. PBS
In vivo:
3 weekly I.A. injection
PBS vs. BMSCs vs. MVs
In vitro:
MVs induced chondrocytes proliferation
in a dose dependent manner and protected
chondrocytes from apoptosis
via bioactive lipid, S1P
In vivo:
MVs significantly accelerated cartilage
recovery as BMSCs. Blocking S1P in vivo
reduced the therapeutic effect of MVs














Storage at −20 ◦C
In vitro:
Control vs. Exo 1 µg/mL vs.
5 ug/mL vs. 10 µg/mL
In vivo:
Exo (100 mg) vs. PBS (100 mL)
In vitro:
Exo groups induced cells proliferation and
migration increase, with dose-dependent
effect; matrix synthesis increase;
apoptosis decrease
In vivo:
In Exo group, initial repair at 2 weeks with
neotissue formation and ECM deposition.
Improved surface regularity and integration
at 6 weeks and complete
integration at 12 weeks.
MSC Exo increase M2 macrophage
infiltration with a concomitant decrease
in M1 macrophages and
inflammatory cytokines







Chondrocytes (age: 3 days)
Mouse macrophages
(age: 3 days)
Exo (mean 112 ± 6.6 nm) and
MVs (mean 223 ± 15.6 nm)
Cell passage: BMSCs 10–20;
Isolation method:
Centrifugation
No storage, freshly use
In vitro:
MVs or Exo (12.5 ng; 125 ng or 1.25 µg)
vs. BM-MSC-CM (1 mL) vs.
BM-MSCs (105 cells).
In vivo:
a single I.A. injection BM-MSCs
(2.5 × 105 cells/5 µL saline) vs. MVs
(500 ng/5 µL) vs. Exo (250 ng/5 µL)
In vitro:




MVs and Exo protected from developing OA











Cell passage: SMSC 5
Isolation method:
Centrifugation




4 weekly I.A injection
sham vs. saline vs. SMSC-140-Exo vs.
SMSC-Exo
In vitro:
SMSC-140-Exo enhanced the proliferation
and migration of ACs without damaging
ECM secretion
In vivo:
SMSC-140-Exo slowed the progression
of early OA and prevent severe damage
to knee articular cartilage.
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Table 2. Cont.
References Animal and OA Model Sources Secretome/Vesicle Types Isolation Method and Storage Study Design Results











(age: within 2 days)
Exo
(38 nm to 169 nm)




Storage at −80 ◦C
In vitro:
CM+Exo vs. CM vs. Exo
In vivo:
2 I.A. injections/week
Exo (1 × 106) vs. PBS
In vitro:
Chondrocyte phenotype maintenance in Exo




Exo alleviated cartilage destruction
and matrix degradation
Zhu et al. 2017

















Storage at −80 ◦C
In vitro:
iMSC-Exo vs. SMSC -Exo
In vivo:
3 weekly I.A. injection
normal vs. iMSC-Exo (1.0 × 1010/mL)
vs. SMSC -Exo (1.0 × 1010/mL) vs.
untreated
In vitro:
Chondrocyte migration and proliferation
were stimulated by both iMSC-Exo and
SMMSC-Exo, with iMSC-Exo exerting
a stronger effect.
In vivo:
iMSC-Exo and SMMSC-Exo both attenuated
OA in the mouse OA model, but iMSC-Exo
had a superior therapeutic effect compared
with SMMSC-Exo.
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3.1. In Vitro Studies
In vitro studies were published from 2017 with a rapidly increasing trend of publications (Figure 3).
Among the 18 in vitro studies, six articles used bone marrow-derived MSCs (BMSCs), four adipose-derived
stem cells (ASCs), two embryonic stem cell-derived MSCs (EMSCs), two commercial (not otherwise
specified) MSCs, one synovial-derived MSCs (SMSCs), one chondrocytes, one infra patellar fat pad
(IPFP)-derived MSCs, and one compared SMSCs with induced pluripotent stem cell line (iPSC)-derived
MSCs. Furthermore, one study compared the effects of secretome, MVs, and Exo compared to BMSCs.
Twelve articles investigated the effect of Exo, four evaluated Exo with MVs, one EVs (without other
details), and one secretome. The most selected method to isolate EVs was differential centrifugation
(five), followed by precipitation-based commercial kits (four), differential centrifugation coupled with
a filtration step (three), filtration (three), differential centrifugation with sucrose density centrifugation
(one), filtration and sucrose density centrifugation (one), while one paper did not report the detailed
isolation protocol (one). Results of in vitro studies were summarized according to:J. Clin. Med. 2019, 8, x FOR PEER REVIEW 2 of 16 
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EVs internalization: EVs [18–23] can be internalized very quickly, already after 30 min from their
administration [20]. Moreover, the kinetic of their uptake reached a maximum after 12–18 h [19,21]
when cells appeared to be saturat , and continued up to the last ev luation performed at 24 h after EVs
additi [19,21]. The intracytoplasmic localiza ion of inte naliz d Exo was i entified in the perinuclear
region [18,19,23].
Effect on viability, proliferation, and migration: A total of 14 paper investigated the effect of EVs
or secretome on cell proliferation, viability, and migration (Table 1) [18,20–32]. Twelv papers r ported
that EVs d rived from MSCs increased the proli eration and/ r the viability of OA ch ndrocytes
or chondrocyte progenitor c lls [18,20–23,25,26,28–32], with a do e dependent effe t [18,21,22,26],
while two papers [24,27] reported no significant effects on chondrocytes viability. One study compared
the effect on chondrocyte proliferation of Exo deriv d from two different MSCs sources [31], iPS-derived
MSCs and SMSCs, finding that Exo from iPS-MSCs ha superior effects than SMSC-Exo. While high
proliferation mediated by SMSCs-Exo was c rrelated with a co comitant d crease of the extracellular
matrix (ECM) components: this was not ob erved with Exo enriched with a particul r micro RNA
(miR-140-5p), as shown by Tao et al. [23]. Finally, seven articles [21,23,25,26,28,30,31] documented that
cell migration increased after Exo administration, showing also dose dependency [21,26,28].
Effect on chondrocyte phenotype: Thirteen papers assessed phenotyp maintenance and
chondrocyte hypertrophy after the treatment with EVs or s cretome [20,21,23–30,32–34]. Regarding
the maintenance or the induction of cho drocyte phenotype, thre studies described the increase of the
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expression of SOX9 [20,25,30], mediated by EVs. Six works analyzed chondrocyte hypertrophy status
after EVs addition [20,24,28–30,32], and four of them showed that the expression of the transcription
factor RUNX2 diminished with EVs [20,28,30,32]. Liu et al. [28] reported that this reduction was
dose dependent. At protein level, four papers observed the decreased expression of type-X collagen
mediated by EVs, either normal [20,24] or overexpressing miR-92a-3p [30] or miR-95-5p [29]. Similarly,
the level of other two hypertrophy markers (alkaline phosphatase and osteocalcin) were lowered [20,24].
Production of cartilaginous ECM: ECM protein expression was investigated in 13
studies [19–21,23,25–30,32–34]. Among these papers, 11 quantified the expression of ECM
components, in particular type-II collagen and aggrecan, in chondrocytes treated with EVs or
secretome [20,23,25–30,32–34]. Nine papers reported induction of type-II collagen and aggrecan
expression by EVs, with a dose dependent effect [28,33,34] and showed a tendency towards better
effects exerted by MVs over Exo [27,33]. Only one study by Tao et al. [23] reported that SMSCs-Exo
diminished the expression of COL2A1 and aggrecan in a dose-dependent manner, but this effect was
reverted with the use of Exo overexpressing miR-140-5p. In general, all papers investigating the
effects of EVs enriched with specific miRNA [25,26,29,30] reported a significant improvement of ECM
protein level. Finally, Exo had positive effects also on Cartilage Oligomeric Matrix Protein (COMP) [21]
and on HAS-1,2,3 levels [19] increase. In particular, Ragni et al. [19] showed that two days after Exo
addition HAS-1 was up-regulated while HAS-3 was down-regulate and the isoform 2 did not show
any significant variation.
Anti-catabolic effect: Twelve of the included papers evaluated the anti-catabolic effect of EVs
on chondrocytes or synovial fibroblasts [19,20,24–30,32–34], showing a general positive effect with
a dual action on catabolic proteins decrease or increase of their inhibitors. The expression of matrix
metalloproteinase 13 (MMP-13) resulted lower in eight studies [19,26–30,32,33], with a dose-dependent
effect [28]; while two papers did not observe any variation [24,25]. In particular, Sun et al. [25]
demonstrated the superiority of Exo-miR-320c in decreasing MMP-13 levels with respect to normal
Exo. Two works reported a tendency of superior effects exerted by MVs over Exo and secretome [27,33]
in reducing MMP-13 expression [33] and MMP activity in a dose-dependent manner [27]. Ragni et al. [19]
showed a reduction of MMP-1 levels at an early time point (2 days). On the other hand, Niada et al. [24]
reported that secretome increased tissue inhibitors of MMPs (TIMP) -1, -2, -3, and -4, supporting that the
minor MMP activity might be ascribed to the production of TIMPs. Three papers [26,33,35], investigated
the expression of ADAMTS5, describing a comparable reduction in Exo and MVs groups, but greater
than the one induced by the secretome [33]. Finally, Vonk et al. [20] showed that collagenase activity
was significantly reduced by EVs administration, with a concomitant increase of Wnt-7a expression,
which could contribute to the prevention of cartilage damage and to the regeneration process.
Anti-inflammatory and Immunomodulatory effect: Positive effects have also been reported for
the anti-inflammatory and immunomodulatory action mediated by secretome or EVs, and described
in six studies [19,20,27,30,33,36], showing the reduction of inflammatory mediators and the increase
of anti-inflammatory molecules. In particular, it was demonstrated that the expression of Cyclooxygenase
2 (COX-2), Interleukin 1 alpha (IL-1α), -1 beta (β), -6, -8, and -17 [20], Tumor necrosis Factor alpha
(TNF-α), IL-6, Microsomal Prostaglandin E Synthase-1 (mPGES-1), inducible Nitric Oxide Synthase
(iNOS), and Prostaglandin E2 (PGE-2) [27] decreases following secretome or EVs administration,
while anti-inflammatory factors like IL-10 increases [27]. Concerning the effects exerted by different
EVs types, secretome was shown to be significantly more effective than Exo in decreasing COX-2
and mPGES-1 expression [27], as well as TNF-α quantity [33]. Conversely, the expression of iNOS
showed a dose-dependent reduction following the administration of Exo and MVs, which both exerted
significantly better results than the secretome [33]. Finally, the study of the polarization of macrophages
phenotype showed that both Exo and MVs diminished their activation [33].
Effect on apoptosis: As increased chondrocyte apoptosis represents another feature of OA
cartilage, six papers investigated the impact of EVs on this cell process [18,22,26,28,32,33], all reporting
a significant decrease in apoptosis rate. Among these, three also demonstrated a dose dependent
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reduction of OA chondrocyte apoptosis [22,28,33], with superior results for Exo versus MVs [33].
One paper studied the effect of Exo overexpressing a long non-coding RNA (KLF3-AS1) [32], showing
that not transfected MSC-Exo significantly reversed IL-1β-mediated chondrocyte apoptosis, and that
KLF3-AS1-Exo consolidated this inhibition.
Autophagy and senescence: Another cell process important for cartilage biology during OA
progression is autophagy, assessed by Wu et al. [26], showing that Exo significantly increased
autophagy in IL-1β-treated chondrocytes. Finally, Tofiño-Viann et al. [36] demonstrated that Exo, MVs,
and secretome significantly reverted mitochondrial membrane increase and oxidative stress induced by
IL-1β, thus causing a reduction in DNA damage and resulting in inhibition of the senescence process.
3.2. In Vivo Studies
In vivo studies were published from 2016 with a rapidly increasing trend of publications (Figure 3).
Among 11 in vivo studies, nine included both an in vitro investigation and an animal model study.
Six studies have been performed in mouse, four in rat, and four in rabbit. Three studies created an
osteochondral defect model and eight an OA model. Eight articles investigated the effect of Exo,
1 of secretome, one of MVs, and one compared Exo with MVs. Regarding the cell source, four used EVs
or secretome from BMSCs, three from EMSCs, two from SMSCs, one from IPFP, and one commercial not
better specified MSCs. The most selected method to isolate EVs was differential centrifugation (four),
followed by ultrafiltration (two), filtration (two), precipitation-based commercial kits (one), and sucrose
density centrifugation (one). All studies showed positive effects after the administration of secretome,
Exo, or MVs in both osteochondral [21,22,35] and OA defect models [23,26,28,30,31,33,34,37]. The results
of in vivo studies have been summarized according to:
Effect on cartilage tissue and ECM deposition: Animal studies showed that Exo was effective
in cartilage surface restoration and ECM deposition [21,26,31,34,35], regenerating a hyaline-like
cartilage completely integrated with the adjacent tissues [31,35]. Zhang et al. [21] demonstrated that
this repair and the deposition of ECM started 2 weeks post-injection and increased over time for up
to 12 weeks. Similar results after Exo and MVs injections were reported, both providing protection
from OA development [33] and showing that both vesicles are equally effective in counteracting tissues
degeneration and promoting cartilage regeneration. Positive effects on cartilage repair and ECM
deposition have also been described for Exo derived from cells over-expressing microRNA [23,30]
or engineered to silence specific genes [28]. These results were superior to those induced by normal
Exo. Finally, Khatab et al. [37] and Xiang et al. [22] demonstrated that the effect of secretome and MVs
injections on cartilage and ECM were the same as those exerted by MSC injection.
Effect on synovial inflammation and cytokines: Two studies addressed this issue, one showing
that Exo increased M2 macrophage infiltration while decreased M1 and inflammatory cytokines [21],
while the other study was unable to demonstrate any effect on synovial inflammation for both secretome
and MSCs [37].
Effect on bone tissue: Regarding subchondral bone, both Exo and MVs were effective in terms
of regeneration: Zhang et al. [21,35] showed complete subchondral bone restoration; Cosenza et al. [33]
described higher bone volume and lower bone degradation at epiphyseal and subchondral level
following MVs or MSCs injections with respect to controls. Conversely, no effect on bone remodeling
was reported by Khatab et al. for both secretome and MSCs [37].
Effect on pain and gait: Another interesting aspect is that Exo injections were able to partially ameliorate
gait abnormality patterns in the OA mouse model [26]. Moreover, Khatab et al. [37] demonstrated that
both secretome and MSCs provided early (day 7) pain reduction in the treated animals.
4. Discussion
The main finding of this systematic review is that the use of secretome and EVs for the treatment
of cartilage pathology and knee OA had pleiotropic effects and overall positive results. In vitro,
both secretome and EVs showed anticatabolic, immunomodulatory, and regenerative properties, and
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in vivo studies confirmed the effectiveness as minimally invasive treatment, with positive effects on
the whole joint.
The literature analysis supports the use of secretome and EVs with an increasing number
of preclinical studies. The overall successful results, coupled with the same low immunogenicity
of MSCs, and potentially fewer legal issues compared to therapies based on cell transplantation [38],
make this biological approach a good candidate for human translatability. The use of secretome and
EVs as a minimally invasive treatment for OA in an in vivo preclinical model showed that it was
equally effective as MSCs in terms of pain improvement and morphological changes [37], and even
proved the superiority of MVs and Exo over BMSCs in terms of joint protection from OA [33]. On the
other hand, the literature analysis also underlined that, despite the increasing interest with many
recent publications, this field is still in its infancy, with several approaches proposed but lacking
the underlying understanding of biological roles and functions. In addition, standardizations and
indications on the most suitable strategies for exploiting the potential of this biological approach are
also still lacking.
With the aim to evaluate the potential of secretome and EVs as new cell derived approaches
for the treatment of knee OA, the available literature was screened for both in vitro and in vivo
studies assessing the role of these biological products in the different physiologic processes involved
in cartilage lesions and OA progression and treatment. Three different cell derived products were
considered: secretome, Exo, and MVs. For this analysis, the secretome group included all studies that
specifically referred to the secretome. Regarding the EVs, they are a heterogeneous population which
has been classified into three classes according to their biogenesis and size: apoptotic bodies, MVs,
and Exo [39]. The apoptotic bodies, the largest EVs population, range from 200 nm to 5000 nm, and they
are secreted by the shedding of the plasma membrane of apoptotic dying cells. The MVs, also called
ectosomes or microparticles, are 200–800 nm sized EVs that are shed from the plasma membrane
of viable cells. Exo, which are 30–200 nm in size, are formed intracellularly and then released within
the multivesicular bodies pathway. However, this classic EVs nomenclature results overburdened
and sometimes confusing [40]. For the purpose of this systematic review EVs have been subdivided
in two different population as small (below 200 nm) and medium-sized EVs (larger vesicles), following
the statement of the of the International Society for Extracellular Vesicles [41], but maintaining the
nomenclature used in all the papers analyzed, Exo and MVs respectively.
The literature analysis showed a great heterogeneity among studies in terms of EVs used, size,
and isolation procedures. The most investigated EVs type is Exo, with a different size range (from 50
to 200 nm), making it difficult to compare among studies or correlate EVs characteristics and in vitro and
in vivo results. Only one study [33] investigated the effect of different EVs types, comparing MVs and
Exo on a chondrocytes culture and an in vivo OA model. The study showed that both EVs exert similar
chondroprotective and anti-inflammatory effects, delaying OA development, leaving the question on
the most suitable approach still open. The isolation procedures represent a critical aspect, since there is
no standardized method to isolate EVs, resulting in different protocols and therefore different products
to be used. The main methods used are differential centrifugation, filtration, and precipitation-based
reagent, but there is a lack of standardized methods to obtain them, possibly contributing to EVs
variability. Moreover, secretome and EVs can be obtained from different cell sources.
This systematic review showed that the most used cell source are currently BMSCs, followed by
ASCs, EMSCs, SMSCs, but there is lack of information available about the difference between vesicles
derived from different cells and thus the optimal cell source to address OA remains elusive. Only one
study [31] compared the effects of Exo secreted by iPS-derived MSCs and SMSCs in vitro. This showed
that they both stimulated chondrocyte proliferation in a dose-dependent manner, but results depended
on the cell source, with superior effect of Exo from iPS-derived MSCs on cell proliferation, at high
concentration, and superior therapeutic effect in attenuating OA in a mouse model.
The proper selection of EVs cell source and also the stage of cell differentiation are actually critical
aspects, since they can determine the characteristics and properties of EVs to fit specific applications
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(such as reducing inflammation, promoting cartilage regeneration and protection from OA features) [38].
Furthermore, the surrounding microenvironment seems to play an active role in determining the
composition of both secretome and EVs cargo, ultimately affecting their action on target cells [42].
Analogously, the type of media and substrate used for cell culture, as well as the use of primary
or immortalized cells can also independently affect secretome and EVs composition [38]. For the
translational potential of secretome and EVs into a clinically available therapeutic option, another key
factor to be considered is the proper dosage [21,22,29,30,33]. In this regard, the literature presents
concordant findings, with all papers that compared different amounts reporting a dose dependent
effect and superior results at the higher quantities. However, no effects of different dosages were
described in the analyzed animal models. In addition, the lack of standardization, also in terms of unit
of measurement employed to express the used amount of EVs and thus the presence of heterogeneous
products, prevents the possibility to identify the best EVs concentration for an optimal effect in terms
of OA treatment. Further efforts should investigate the protocols to optimize secretome and EVs
production toward OA treatment.
While studies focusing on the most suitable cell source and dosage could foster the clinical
translatability of this biological approach, research efforts are already invested into the investigation
on how to further develop this field by optimizing secretome and EVS potential. In this light,
among the beneficial effects mediated by EVs, one aspect remains critical: Tao et al. [23] reported that
chondrocytes treated with normal Exo decreased ECM proteins expression. On the contrary, the treatment
with miR-140-5p-Exo, expressed during the development and homeostasis of cartilage and lowered
in OA [43], did not affect ECM protein secretion. miRNAs are important Exo components and their
role has been demonstrated in repressing chondrocytes inflammation, promoting chondrogenesis, and
inhibiting cartilage degeneration. Considering these effects on chondrocytes, five studies [23,25,26,29,30]
investigated the overexpression of different miRNAs in Exo, describing in general better results compared
to the normal Exo in terms of cell proliferation, gene expression, ECM components’ production in vitro
and inhibition of cartilage degradation in vivo. Furthermore, Liu et al. [32] described the effect of over
expressing a long non-coding RNA KLF3-AS1, a competitive endogenous RNA which was able to inhibit
miR-206, a miRNA that resulted overexpressed in OA.
Another feature of OA is synovial inflammation, notably characterized by activation of monocytes
and macrophages. One major immunosuppressive effect of BM-MSCs is to inhibit macrophage
activation and to induce a shift from M1 pro-inflammatory to M2 anti-inflammatory phenotype [44].
In this light, Cosenza et al. [33] demonstrated that both MVs, Exo, and BM-MSCs inhibited in vitro
macrophage activation to a similar extent. On the contrary, Khatab et al. [37] did not report any
significant change on synovial thickness or synovial macrophages phenotypes using secretome injection
in an OA mouse model, although several significant moderate correlations between macrophage
phenotypes and OA characteristics were found. Another aspect was investigated: different types
of stress can lead to a premature cellular senescence. Among these, chronic inflammation can increases
oxidative stress driving to cellular senescence, a process that can contribute to the development and
progression of OA [45]. In this context, Exo was able to revert the oxidative stress induced by IL-1β,
thus causing a reduction in DNA damage and resulting in inhibition of the senescence process [36].
All these investigated targets confirmed the pleiotropic effects of secretome and EVs, which led
to positive effects also in vivo. Exo injections were able to partially ameliorate the gait abnormality
patterns in the OA mouse model [26], and secretome injections provided early (day seven) pain
reduction in treated animals, similar to MSCs [37], further supporting the translational potential of this
biological approach. On the other hand, this systematic review also underlined several critical aspects
needing additional investigation to further develop and optimize this biological treatment strategy.
The promising in vitro and in vivo results support the potential of this new treatment approach,
opening new perspectives for cell-based therapies. Secretome and EVs could require less complex
regulation procedures than treatments based on cell transplantation, while providing similar results
of MSCs. The standardization of protocols could further facilitate clinical translatability. In this light,
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research efforts are required for the identification of the proper cell source, the best preparation protocol
and the most suitable target and, in the end, for the translation of the preclinical promising findings
into clinical trials to confirm the potential of secretome and EVs as a minimally invasive biological
treatment to address knee OA.
5. Conclusions
This systematic review of the literature underlined an increasing interest towards this emerging
field, with overall positive findings. Promising in vitro results have been documented in terms
of enhanced cell proliferation, reduction of inflammation, and down-regulation of catabolic pathways
while promoting anabolic processes. The positive in vitro findings were confirmed in vivo, with studies
showing positive effects on cartilage, subchondral bone, and synovial tissues in both OA and
osteochondral models. However, several aspects remain to be clarified, like the different effects
induced by EVs and secretome, the most suitable cell source and production protocol, as well as the
identification of patients that may benefit more from this new biological approach for the treatment
of knee OA.
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